Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study

Table 2 Univariate and multivariate analysis for leptomeningeal metastasis incidence

Univariate analysis (N = 224)
Variable name	HR	95% CI for HR		p-value
Age (≥65 vs <65)	0.71	0.34	1.48	0.357
Gender (Male vs female)	1.69	0.87	3.29	0.120
Smoking status (Former or current vs Never)	1.91	0.97	3.75	0.062
Histology (Adenocarcinoma vs Others)	2.14	0.29	15.65	0.453
EGFR mutations (Exon19 deletion vs Others)	0.46	0.23	0.89	0.021*
T (T2–4 vs T0–1)	0.60	0.30	1.20	0.151
N (N1–3 vs N0)	1.14	0.53	2.43	0.740
M (M1c vs Others)	1.19	0.59	2.40	0.621
Clinical stage (Recurrence vs IV)	2.07	0.97	4.43	0.060
Brain metastasis (Yes vs No)	1.32	0.67	2.59	0.416
Bone metastasis (Yes vs No)	1.29	0.66	2.50	0.455
Liver metastasis (Yes vs No)	2.44	1.06	5.61	0.035*
Adrenal metastasis (Yes vs No)	1.30	0.31	5.44	0.722
Metastatic status (Polymetastasis vs Oligometastasis)	0.19	0.07	0.55	0.002*
First-line EGFR TKIs
Gefitnib	Reference
Erlotinib	0.46	0.14	1.55	0.213
Osimertinib	1.08	0.37	3.13	0.887
Icotinib	0.63	0.22	1.82	0.392
Afatinib	1.93	0.26	14.45	0.524
T790M (Yes vs No)	0.56	0.29	1.11	0.099
Chemotherapy (Yes vs No)	0.79	0.40	1.53	0.475
Antiangiogenic therapy (Yes vs No)	1.04	0.52	2.08	0.906
Immunotherapy (Yes vs No)	1.39	0.42	4.54	0.587
Chest radiotherapy (Yes vs No)	0.46	0.19	1.11	0.084
WBRT (Yes vs No)	1.43	0.73	2.78	0.296
Use of Osimertinib (Yes vs No)	0.38	0.19	0.79	0.009*
Multivariate analysis (N = 224)
Variable name	HR	95% CI for HR		p-value
EGFR mutation (Exon19 deletion vs Others)	0.34	0.16	0.72	0.004*
T790M (Yes vs No)	1.50	0.53	4.23	0.446
Metastatic status (Polymetastasis vs Oligometastasis)	0.13	0.04	0.39	0.000*
Use of Osimertinib (Yes vs No)	0.33	0.11	0.96	0.042*

Adjust model adjust for multivariate analysis: Smoking status, EGFR mutations, Clinical stage, Liver metastasis, Metastatic status, T790M, Chest radiotherapy, Use of Osimertinib
HR hazard ratio, CI confidence interval, EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors, WBRT whole brain radiation therapy
* P<0.05 was considered significant

ISSN: 1471-2407